149 related articles for article (PubMed ID: 22966847)
1. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols.
Ribera JM; García O; Fernández-Abellán P; Lavilla E; Bernal MT; González-Campos J; Brunet S; Monteserín MC; Montesinos P; Sarrá J; Calbacho M; Alvarez-Larrán A; Tormo M; Oriol A;
Br J Haematol; 2012 Nov; 159(4):485-8. PubMed ID: 22966847
[No Abstract] [Full Text] [Related]
2. Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance.
Ottmann O
Lancet Haematol; 2018 Dec; 5(12):e606-e607. PubMed ID: 30501865
[No Abstract] [Full Text] [Related]
3. [Acute lymphoblastic leukemia].
Hatta Y
Rinsho Ketsueki; 2014 Feb; 55(2):185-90. PubMed ID: 24598186
[No Abstract] [Full Text] [Related]
4. [Efficacy and safety of tyrosine kinase inhibitor dasatinib plus chemotherapy in the treatment of childhood Philadelphia chromosome-positive acute lymphoblastic leukemia].
Guo Y; Liu TF; Yang WY; Wang SC; Ruan M; Chen XJ; Zhang L; Liu F; Zou Y; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):634-7. PubMed ID: 26108329
[No Abstract] [Full Text] [Related]
5. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
6. Advanced Philadelphia chromosome positive acute lymphoblastic leukemia patients relapsed after treatment with tyrosine-kinase inhibitors: successful response to clofarabine and cyclophosphamide.
Vitale A; Grammatico S; Capria S; Fiocchi C; Foà R; Meloni G
Haematologica; 2009 Oct; 94(10):1471-3. PubMed ID: 19608688
[No Abstract] [Full Text] [Related]
7. Philadelphia chromosome-positive Acute Lymphoblastic Leukemia.
Forghieri F; Luppi M; Potenza L
Hematology; 2015 Dec; 20(10):618-9. PubMed ID: 26574786
[No Abstract] [Full Text] [Related]
8. Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives.
Malagola M; Papayannidis C; Baccarani M
Ann Hematol; 2016 Apr; 95(5):681-93. PubMed ID: 26891878
[TBL] [Abstract][Full Text] [Related]
9. Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
Haddad FG; Kourie HR; Saleh K
Br J Haematol; 2023 Sep; 202(6):1084-1086. PubMed ID: 37525325
[TBL] [Abstract][Full Text] [Related]
10. [Successful induction and long-term molecular remission with imatinib mesylate and chemotherapy in a case of Ph-positive acute lymphoblastic leukemia].
Hirayama Y; Sakamaki S; Takayanagi N; Tsuji Y; Sagawa T; Chiba H; Maeda M; Matsunaga T; Kato J; Niitsu Y
Rinsho Ketsueki; 2003 May; 44(5):334-8. PubMed ID: 12822409
[TBL] [Abstract][Full Text] [Related]
11. High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL.
Tasian SK; Hurtz C; Wertheim GB; Bailey NG; Lim MS; Harvey RC; Chen IM; Willman CL; Astles R; Zebrowski A; Reshmi SC; Li MM; Frey NV; Luger SM; Carroll M; Perl AE
Leukemia; 2017 Apr; 31(4):981-984. PubMed ID: 27932787
[No Abstract] [Full Text] [Related]
12. Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Stock W
Clin Adv Hematol Oncol; 2008 Jul; 6(7):487-8. PubMed ID: 18654114
[No Abstract] [Full Text] [Related]
13. Can we increase the cure rate of adults with acute lymphoblastic leukemia?
Arlin ZA; Feldman EJ
Leukemia; 1989 Apr; 3(4):318-20. PubMed ID: 2927182
[No Abstract] [Full Text] [Related]
14. [Treatment strategy for the patients with Philadelphia chromosome negative acute lymphoblastic leukemia in first remission].
Takeuchi J
Rinsho Ketsueki; 2010 Jul; 51(7):460-3. PubMed ID: 20693763
[No Abstract] [Full Text] [Related]
15. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
[TBL] [Abstract][Full Text] [Related]
16. [Cytogenetic study of acute and chronic leukemias].
Conte G; Torrens M; Larraín C; Be C; Daher V; Youlton R
Rev Med Chil; 1989 Feb; 117(2):135-41. PubMed ID: 2487950
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
19. Time to tune the treatment of Ph+ ALL.
Yanada M
Blood; 2015 Jun; 125(24):3674-5. PubMed ID: 26069331
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
